Shares in Depomed Inc. on Friday gained nearly 10 percent on news that the FDA approved Proquin XR, a once-daily, extended-release formulation of ciprofloxacin hydrochloride that the specialty pharmaceutical company soon plans to partner. (BioWorld Today) Read More
